The role of tumor necrosis factor-alpha and other cytokines in depression: What dermatologists should know

Journal of Dermatological Treatment

Volumn 24, Issue 2, 2013, Pages 148-152

  Kannan, Swati ^a   Heller, Misha M ^b   Lee, Eric S ^c   Koo, John Ym ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic agents; Cytokines; Depression; Psoriasis; Tumor necrosis factor alpha antagonists

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AMFEBUTAMONE; C REACTIVE PROTEIN; CITALOPRAM; ETANERCEPT; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; NORADRENALIN; PEGINTERFERON; PLACEBO; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; BECK DEPRESSION INVENTORY; BODY MASS; DEPRESSION; DERMATOLOGIST; DISEASE ASSOCIATION; DRUG EFFECT; HEPATITIS C; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INNATE IMMUNITY; LETHARGY; LOCOMOTION; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REVIEW; SMOKING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; DEPRESSIVE DISORDER; HUMANS; INTERLEUKIN-6; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875314805     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.619159     Document Type: Review

References (24)

1. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812-818.
2. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159: 704-710.
3. Evers AW, Lu Y, Duller P, van der Valk PG, Kraaimaat FW, van de Kerkhof PC. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152: 1275-1281. (Pubitemid 40933429)
4. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19:47-57. (Pubitemid 40432507)
5. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry. 2008;23:421-429.
6. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56. (Pubitemid 350295688)
7. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009;30:497-521.
8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31. (Pubitemid 43083561)
9. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
10. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519-548.
11. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25:335-339.
12. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375-388. (Pubitemid 35470357)
13. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci. 1992;13:24-28.
14. Krueger JM, Takahashi S, Kapas L, Bredow S, Roky R, Fang J, et al. Cytokines in sleep regulation. Adv Neuroimmunol. 1995;5:171-188.
15. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology. 2000;22:566-580. (Pubitemid 30219401)
16. Bianchi M, Sacerdote P, Ricciardi-Castagnoli P,Mantegazza P, Panerai AE. Central effects of tumor necrosis factor alpha and interleukin-1 alpha on nociceptive thresholds and spontaneous locomotor activity. Neurosci Lett. 1992;148: 76-80. (Pubitemid 23007708)
17. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237-241. (Pubitemid 35351283)
18. Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD. Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. J Viral Hepat. 2011;18:e284-91.
19. Clement HW, Buschmann J, Rex S, Grote C, Opper C, Gemsa D, et al. Effects of interferon-gamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm. 1997;104:981-991. (Pubitemid 28031665)
20. Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry. 2006;60:882-888. (Pubitemid 44527894)
21. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903-907.
22. Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun. 2011;25:256-259.
23. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35. (Pubitemid 43038667)
24. Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med. 2002;64:835-840.